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Abstract: Fruit seeds high in antioxidants have been shown to have anticancer properties 
and enhance host protection against microbial infection. Recently we showed that a single 
oral dose of Salmonella enterica serovar Typhimurium expressing a truncated human inter-
leukin-2 gene (SalpIL2) is avirulent, immunogenic, and reduces hepatic metastases through 
increased natural killer cell populations in mice. To determine whether antioxidant compounds 
enhance the antitumor effect seen in SalpIL2-treated animals, we assayed black cumin (BC), 
black raspberry (BR), and milk thistle (MT) seed oils for the ability to reduce experimental 
hepatic metastases in mice. In animals without tumor, BC and BR oil diets altered the kinetics 
of the splenic lymphocyte response to SalpIL2. Consistent with previous reports, BR and BC 
seed oils demonstrated independent antitumor properties and moderate adjuvant potential with 
SalpIL2. MT oil, however, inhibited the efficacy of SalpIL2 in our model. Based on these data, 
we conclude that a diet high in antioxidant oils promoted a more robust immune response to 
SalpIL2, thus enhancing its antitumor efficacy.
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Introduction
Attenuated strains of Salmonella enterica (S. enterica) serovar Typhimurium were 
first explored as delivery vectors for anticancer therapeutics in the mid 1990s.1,2 Since 
then, S. enterica tumor vaccines have shown efficacy in experimental animal models 
against multiple tumor types including colorectal, melanoma, breast, bone, spine, liver, 
pancreatic, prostate, and lung.3–11 In our experimental models, we have focused on 
the efficacy of an avirulent and highly immunogenic strain, S. enterica Typhimurium 
χ4550, that was engineered to express a human interleukin-2 (IL-2) gene in primary 
and experimental metastasis models.12–14 In these studies, S. enterica χ4550 express-
ing a human IL-2 gene was effective at reducing the number and volume of hepatic 
metastases both when administered before and after tumor introduction. Decreased 
tumor burden in these models was inversely correlated with increased hepatic natu-
ral killer (NK) cell populations and when depleted, S. enterica χ4550’s antitumor 
properties were abolished.15 Most recently, we have demonstrated that S. enterica 
Typhimurium expressing a C-terminal truncated human IL-2 gene (SalpIL2) reduced 
osteosarcoma lung metastases and significantly increased the number of detectable 
NK cells in the lung as compared to S. enterica-vector control or saline gavaged 
animals.16,17 In addition, in the serum of animals with pulmonary osteosarcoma metas-
tases, a single oral dose of SalpIL2 altered the detection of several proinflammatory 
cytokines associated with tumor progression.18 In Rag-1 knockout mice, which do OncoTargets and Therapy 2011: 4 submit your manuscript | www.dovepress.com
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not have functional T-cells, SalpIL2 continued to decrease 
tumor burden. Thus, SalpIL2’s antitumor properties appear 
to be independent of T cell contribution.
Adjuvants, such as cycloxygenase-2 (Cox2) inhibitors 
appeared to enhance the antitumor efficacy of our attenuated 
S. enterica strain. When administered with Cox2 inhibitors, 
S. enterica significantly reduced the number and volume 
of hepatic metastases as compared to all other treatment 
types.19 However, due to insolubility of Cox2 inhibitors 
in water, controlled dose delivery of these drugs in the 
drinking water of mice required multiple suspension doses 
daily. Similar to pharmaceutical Cox2 inhibitors, fruit seed 
extracts from black cumin (BC; Nigella sativa), black 
raspberry (BR; Rubus occidentalis), and milk thistle (MT; 
Silybum marianum) have been shown to contain high levels 
of antioxidants and have inhibitory effects on Cox2.20–23 
In addition, BC and BR seed extracts suppress activity of 
NFκB, a proinflammatory transcription factor shown to be 
hyperactive in many cancers.24,25 Anticancer properties of 
extracts from BC, BR, and MT oils have been demonstrated 
by observation of decreased tumor burden in oil treated 
animals.26–28 The application of antioxidant compounds also 
appears to be clinically beneficial. Freeze-dried BR gels, 
when applied directly to premalignant oral lesions, induced 
regression of cancerous tissues.21,29 However, to the best of 
our knowledge, BR oil has not been reported to affect the 
growth of syngeneic tumors in organs, nor have BC, BR, 
and MT oils been shown to be efficacious as adjuvants with 
immunomodulatory anticancer therapies.
In these studies, we sought to test the hypothesis that BC, 
BR, and MT antioxidant oils would enhance the efficacy 
of SalpIL2 in an experimental murine model of hepatic 
metastases. In this report, we show that several antioxidant 
compounds augment the cell-mediated immune response to 
SalpIL2 in nontumor bearing mice. In addition, antioxidant 
oils provide adjuvant antitumor properties to SalpIL2 and 
appear to directly decrease the growth of experimental 
hepatic metastases. In contrast to BC and BR oils, MT oil 
abrogated the ability of SalpIL2 to reduce the number of 
hepatic tumors in our model.
Materials and methods
Quantification of lipid-soluble 
antioxidants in selected oils
Fruit seed oils provided by Botanic Oil Innovation (Spooner, 
WI) were examined for lipid-soluble antioxidant capacities 
using an ACL kit to measure the capacity of lipophilic 
substances following the directions as described by the 
manufacturer (Analytik Jena, Spring, TX). Briefly, fruit seed 
oils were dissolved in hexane (20%) and methanol (79%) and 
run in triplicate to determine Trolox equivalents, a derivative 
of vitamin E, by chemiluminescence using the Photochem 
instrument (Analytik Jena).
Bacteria
The avirulent, but highly immunogenic S. enterica serovar 
Typhimurium strain χ4550, a well-characterized adenylatecy-
clase, cyclic adenosine monophosphate receptor protein, and 
aspartate semialdehyde dehydrogenase (asd) deletion mutant, 
was a kind gift from Dr Roy Curtiss III   (Washington Univer-
sity, St Louis, MO). Plasmid pIL2, constructed by insertion 
of a C-terminal truncated human IL-2 cDNA immediately 
downstream from the trc promoter in pYA29230 which con-
tains an S. enterica asd cDNA for stable maintenance, was 
electroporated into S. enterica Typhimurium χ4550 and the 
resultant strain was renamed SalpIL2.   SalpIL2 was cultured 
overnight at 37°C in   Luria-Bertani broth (Difco Laboratories, 
Detroit, MI), washed and reconstituted to approximately 
109 mL-1 colony forming units (CFU) in Hank’s Balanced 
Salt Solution (HBSS). Bacteria aliquots were stored as a 
15% glycerol stock in liquid nitrogen until used in experi-
ments. On the day of oral inoculation, bacterial stocks were 
allowed to thaw to room temperature and CFU concentra-
tion was confirmed by serial dilution on   MacConkey agar 
plates (Becton, Dickinson, and Company, Bedford, MA). 
The University of Minnesota Institutional Biosafety Com-
mittee approved the use of SalpIL2 in all experiments as   
described.
Mice
Female 6 to 8 week old C57BL/6 mice were purchased from 
Harlan Sprague Dawley (Indianapolis, IN) and allowed to 
acclimate for a minimum of 7 days in specific pathogen free 
conditions. After inoculation with SalpIL2, all experimental 
animals were transferred to biosafety level two for the 
remainder of the study. Antioxidant oils were mixed with 
ground standard mouse chow (Harlan) to make a homogenous 
10% w/w meal. Experimental mice were given ground 
meal or meal mixed with antioxidant oil daily and drinking 
water was supplied ad libitum. All animals were housed in 
microisolator cages and cared for by trained personnel from 
Research Animal Resources. The University of Minnesota 
Institutional Animal Care and Use Committee approved all 
protocols.OncoTargets and Therapy 2011: 4 submit your manuscript | www.dovepress.com
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Murine adenocarcinoma tumor model
MCA-38 syngeneic tumors were propagated in naïve 
C57BL/6 mice as previously described.12 Briefly, 4 × 106 
tumor cells were injected subcutaneously into the hind flank 
and allowed to grow until a palpable mass was present. 
Anesthetized animals were euthanized and the tumor mass 
was aseptically removed, minced and digested in 0.1% 
DNase, 0.1% hyaluronidase, and 0.1% collagenase (Sigma 
Co, St Louis, MO) in Dulbecco’s Modified Eagle’s Medium 
(DMEM) with 10% fetal bovine serum (Sigma) for 2 hours 
with gentle agitation. The tumor solution was filtered through 
150 µm Nitex mesh (Sefar America, Kansas City, MO), 
centrifuged at 500 × g for 10 minutes and resuspended in 
HBSS twice before enumeration by trypan blue exclusion. 
5 × 104 cells were injected into the spleen of anesthetized 
animals via transabdominal incision and allowed to circulate 
for 3 minutes. The spleens were removed and the animals 
were allowed to recover on warming pads until ambulatory. 
Animals were sacrificed and hepatic metastases were visually 
enumerated 14 days posttumor injection.
Splenic and hepatic lymphocyte 
enrichment
Spleens from nontumor bearing animals were collected 
for splenic lymphocyte population analysis on day 3, 7, 
14, and 21-post oral gavage and start of antioxidant oil. 
After 14 days of tumor growth, tumor-burdened livers were 
ground in DMEM with 10% fetal goat serum using sterile 
glass stoppers. The tissue slurry was filtered through 150 µm 
Nitex mesh, layered on top of lymphocyte separation medium 
(Mediatech, Inc, Herndon, VA) and centrifuged at 300 × g 
for 1 hour. Splenic, hepatic, and tumor lymphocytes were 
collected from the Ficoll-hypaque layer and serially washed 
with phosphate buffered saline with 1% bovine serum 
albumin and 0.1% sodium azide (Sigma).
Flow cytometry
Splenic and hepatic lymphocytes were examined for 
cells reactive with anti-NK1.1, anti-CD4, and anti-CD8 
fluorochrome-conjugated anti-mouse monoclonal antibodies 
(BD Biosciences Pharmingen, San Diego, CA). Lymphocytes 
were incubated with the antibodies at 4°C for 30 minutes. 
After washing, analysis was performed with FACS cancyto-
fluorometer (Becton-Dickinson, Grenoble, France) using Cell 
Quest Pro software (Becton-Dickinson). Lymphocytes were 
gated by side and forward scatter profiles. Data presented is 
based on 10,000 gated events.
Statistical analyses
Tumor number, volume, and splenic and hepatic lymphocyte 
populations were recorded for each mouse and used to 
calculate the mean values for each experimental cohort. All 
differences between groups were determined by Fisher’s 
exact test and ANOVA using StatView software (v 5.0.1; 
SAS Institute, Cary, NC). In the following sections of the 
manuscript we describe the results as significant (P < 0.05) 
or "tended/marginally" significant as (P < 0.10).
Results
The lipid-soluble antioxidant capacities of BC, BR, BC+BR, 
and MT oils were examined. The combination BC+BR 
seed oil displayed higher antioxidant capacities (25.9 ± 0.2) 
in equal combination as compared to individual oils 
(BC, 21.0 ± 0.1 and BR, 19.8 ± 0.6). In contrast, MT seed 
oil displayed the lowest levels of lipid-soluble antioxidants 
(1.3 ± 0.2) of the oils tested.
Bc and Br enhance cellular immune  
response to SalpIL2
On day 14, NK cell populations were increased (P , 0.10) 
in animals administered SalpIL2 with or without BC+BR 
oil diet (10% w/w) compared to saline and oil-only groups 
(Figure 1A). On day 21, SalpIL2 with BC+BR significantly 
increased NK cell populations over control and combination 
oil-only groups. SalpIL2 with or without BC+BR increased 
CD8+ T cell populations significantly by day 7 over saline 
control and oil-only groups (Figure 1B). By day 21, however, 
all experimental groups had significantly lower splenic 
CD8+ and CD4+ T cell populations than control animals 
(Figure 1B and 1C).
Bc and Br enhance the nK cell response 
to SalpIL2 in tumor burdened animals
We next used a hepatic metastasis model to screen whether 
NK cell populations, increased from BC+BR and SalpIL2 
administration (Figure 1A) would reduce tumor burden 
in vivo. Consistent with our previous studies, SalpIL2 tended 
to reduce the volume of hepatic metastases by 78% in our 
model (P < 0.10). All experimental treatments, for example, 
BC+BR oil with and without SalpIL2, did not have signifi-
cantly reduced tumor number and volume as compared to 
control animals (Figure 2A and 2B). Hepatic NK cell popula-
tions were significantly increased by SalpIL2 alone (272%) or 
SalpIL2 with BC+BR combination oil (412%) as compared 
to the   controls (all P < 0.05). Mice given the combination of OncoTargets and Therapy 2011: 4 submit your manuscript | www.dovepress.com
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SalpIL2 with BC+BR oil tended to have increased NK cell 
populations compared to animals only given SalpIL2 (Figure 
2C; P , 0.10). CD8+ and CD4+ T cells populations were 
not significantly different across the experimental groups 
(Figure 2D and 2E).
Bc oil diet reduces hepatic metastases
Although the combination BC+BR seed oils did not 
significantly decrease tumor number and volume in our 
hepatic metastasis model, we examined whether either BC or 
BR oil alone may enhance the antitumor efficacy of SalpIL2. 
Similar to the BC+BR combination oil diet, a BC seed oil 
diet did not significantly decrease the number of hepatic 
metastases. A diet with BC oil alone, however, reduced tumor 
volume by 74% and when administered with oral SalpIL2, 
significantly decreased tumor volume 75% as compared to 
control animals (Figure 3B; all P < 0.05). The reduction of 
tumor volume was similar to SalpIL2-only treated animals 
(91%). The antitumor effect observed by BC oil appeared 
to be independent of increased NK and CD8+ T cell popu-
lations. Only SalpIL2-treated animals, with or without BC 
oil, displayed significantly higher NK cell populations as 
compared to controls (Figures 3C and 3D; P < 0.05). Lastly, 
SalpIL2 with BC oil treated animals displayed a significant 
29% reduction in CD4+ T cell population at the experimental 
endpoint (Figure 3D) (P < 0.05).
Br oil diet has treatment  
and preventative potential  
on hepatic metastases
In our model, a diet high in BR seed oil significantly 
decreased tumor volume, not tumor number, by 47% as 
compared to controls (Figure 4A and 4B; P < 0.05). No 
significant additional benefit in reduction of tumor volume 
was observed in animals administered SalpIL2 with (61%) 
or without BR seed oil (64%). In hepatic lymphocyte popula-
tions, however, only animals treated with SalpIL2 and BR oil 
had significantly increased NK cells (219%) in the tumor-
burdened animals when compared to control (Figure 4C; 
P < 0.05). There were no significant changes in T cell popula-
tions between treatment groups. Previously, we showed that 
inoculation of mice with S. enterica 7 days prior to tumor 
injection provided protection against the establishment of 
hepatic metastases. Similar to administering a diet of BR 
oil 3 days after tumor injection, BR oil alone significantly 
reduced the volume not number of hepatic metastases by 
45% as compared to controls (Figures 5A and 5B; P < 0.05).   
Animals given SalpIL2 with BR oil had similar reduction in 
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Table of significance (P < 0.05)
Day 21
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Cell Day Group(s) Group(s)
NK 21 Control SalplL2//BC+BR
CD8 21 Control All other groups
CD 42 1 Control All other groups
5
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B
Figure 1 effect of combination antioxidant seed oil on the splenic lymphocyte response to SalpIL2 in mice. Splenic natural killer (nK) (A), cD 8+ T (B), and cD 4+ T cell 
populations (C) as determined by flow cytometry in response in animals fed a diet consisting of equal amounts of black raspberry (BR; Rubus occidentalis), black cumin (BC; 
Nigella sativa) seed oils (), administered a single oral dose of SalpIL2 () or SalpIL2+Bc+Br oil () starting on day 0 as compared to control animals ().
Notes: The table insert indicates statistical significance between groups. Data are mean ± standard deviation from one experiment, n = 5 mice per group.OncoTargets and Therapy 2011: 4 submit your manuscript | www.dovepress.com
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tumor number and volume to SalpIL2 alone, 81%, 98% and 
70%, 96% respectively as compared to controls (P < 0.10). 
Only animals administered SalpIL2 with BR oil showed a 
significant 298% increase in NK cell populations as com-
pared to control animals (Figure 5C; P < 0.05). SalpIL2-only 
animals had a marginally significant increase of 260% in NK 
cell populations compared with controls (P < 0.10). Only 
CD8+ T cell populations were significantly altered between 
BR oil SalpIL2 treatment groups (Figure 5D; P < 0.05).
Br oil diet augmented cellular immunity 
to SalpIL2
To further elucidate the antitumor efficacy of BR seed oil, we 
examined the effect of BR oil diet on the splenic lymphocyte 
populations in SalpIL2-treated mice. BR oil with SalpIL2 
increased NK cells by day 3 over control animals (5.7 to 4.7 
respectively; Figure 6A; P < 0.05), which has not previously 
been observed in SalpIL2-treated animals.18 By days 7 and 
14 however, increased NK-cell populations by SalpIL2 were 
independent of BR oil treatment. With respect to CD8+ T cell 
populations, SalpIL2 with BR oil significantly increased CD8+ 
T cell populations on days 3 and 14 compared to SalpIL2-
treated and control animals (Figure 6B; P < 0.05). SalpIL2 and 
BR oil treatment also affected CD4+ T cell populations. By day 
14, SalpIL2 significantly decreased CD4+ T cell populations 
(P < 0.05), while SalpIL2 with BR oil appeared to negate the 
SalpIL2-dependent drop in CD4+ T cells (Figure 6C).
MT seed oil abrogates the antitumor 
efficacy of SalpIL2
As demonstrated in Figure 5, the antitumor effect of 
SalpIL2 is most evident in animals when delivered prior to 
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Figure 2 effect of combination antioxidant seed oil on the SalpIL2 anti-tumor response in mice. On Day 0, 5 × 104 MCA-38 cells were injected intrasplenically to naïve 
animals. A single oral administration of SalpIL2 and initiation of a diet consisting of equal amounts of black raspberry (BR; Rubus occidentalis), black cumin (BC; Nigella sativa) 
seed oils 10% w/w was given to animals on Day 3. Animals were maintained for a total of 14 days prior to collection of tumor and hepatic lymphocyte data (see diagram 
above). Tumor number (A) and tumor volume (B) in animals fed a Bc+Br with or without SalpIL2. hepatic natural killer (nK) (C), cD8+ T (D), and cD4+ T cell response 
(E) to SalpIL2 and antioxidant oils in tumor burden mice at the experimental endpoint. 
Notes: Bars indicate significance between groups. Data was normalized to percent of control and presented as ± standard deviation from one experiment with n = 4 mice 
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tumor administration. MT oil, however, appeared to inhibit 
SalpIL2’s ability to reduce tumor number (98% to 37%; 
P , 0.10; Figure 7A) and volume (99% to 7%; P , 0.01; 
Figure 7B). MT oil appeared to reduce the NK cell response 
to SalpIL2 as NK cell populations were significantly increased 
in animals given SalpIL2 with MT oil (255%) and SalpIL2 
alone (335%; Figure 7C). Interestingly both MT oil (315%) 
and SalpIL2 alone (387%) increased CD8+ T cell populations 
as compared to controls (Figure 7D), whereas, SalpIL2 with 
MT oil (176%) showed a significant reduction in CD8+ T cell 
populations as compared to SalpIL2 alone. SalpIL2 increased 
the number of hepatic CD4+ T cells (376%) as compared to 
controls, which was significantly increased with respect to 
all other experimental groups.
Discussion
In this report, we investigated whether several known 
antioxidant seed oils could reduce hepatic metastasis or 
enhance the antitumor efficacy of attenuated S. enterica 
Typhimurium. Consistent with previous reports on synergistic 
antioxidant capacities upon mixing oils,31 we show, compared 
to individual oils, the combination of BC+BR had increased 
antioxidant capacity. When given to mice without tumors, 
the combination of BC+BR oil with SalpIL2 resulted in 
an increase in splenic NK cells at day 21. The BC+BR 
combination oil was synergistic with SalpIL2 and increased 
hepatic NK cells populations, however, the number and 
volume of hepatic metastases were not significantly decreased. 
Perhaps due to the increased cell-mediated immune response 
to SalpIL2, the addition of BC+BR oil to the diet may have 
provided an increased clearance of SalpIL2. Thus, additional 
doses may be required to maintain the same level of SalpIL2 
infection and demonstrate a significant difference between 
SalpIL2 with and without BC+BR oil diet.
Since, BC and BR oils individually have displayed 
significant antitumor properties in other models,26,27,32 we 
next asked whether individual BC or BR oils have the ability 
to reduce tumor burden in our hepatic metastasis model. BC 
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oil significantly reduced the volume, but not the number of 
hepatic tumors, suggesting that the consumption of BC oil 
can reduce tumor growth in the liver. The effect of BC oil in 
our model appears to be dose-dependent, as BC oil mixed 
equally with BR oil did not significantly reduce tumor bur-
den without SalpIL2. The protective properties of BC oil 
against tumor initiation may be the result of the combination 
of antioxidant compounds within the extract,33 and appears 
to not be directly correlated to its lipid-soluble antioxidant 
content. Thymoquinone (TQ), a component of BC seed oil, 
has demonstrated inhibitory effects on Cox-1 expression 
and prostaglandin E-2 production; necessary components of 
the Cox-dependent inflammatory response.34 Similar to our 
data, TQ and BC oil reduced tumorigenesis and xenograft 
growth in animal models of colon and prostate cancer.32,35 
The anti-inflammatory properties of BC oil may account for 
the decreased CD4+ T cell populations, however, increased 
NK or CD8+T cells in SalpIL2-treated animals may suggest 
a shift in the type of inflammatory response in tumor-bearing 
mice. Some CD4+ T cell populations, specifically “regulatory” 
T cells, appear to contribute to a tumor’s ability to resist killing 
by the immune system.36 In contrast, regulatory T cells have 
also been correlated with less advanced colorectal disease.37–39 
Therefore, depending on the severity of disease, regulatory 
T cells may be an attractive target for reprogramming local 
tumor immune cell populations. In order to more fully inter-
pret our results in this regard, further characterization of tumor 
CD4+ T cells must be performed.
Similar to BC oil, BR oil alone significantly reduced tumor 
volume and appeared to enhance the NK cell response to 
  SalpIL2 in mice with established metastases. Since tumor num-
ber was not significantly reduced, we interpreted these data to 
suggest that BR oil reduced the growth rather than induced 
regression of tumor. Although SalpIL2 alone marginally 
increased hepatic NK cells, the addition of BR oil significantly 
increased NK cells in tumor bearing mice, suggesting BR oil 
enhanced the NK cell response to SalpIL2. This observation 
was consistent in our experiments in nontumor burdened ani-
mals, as BR oil appeared to also increase the NK cell response 
to SalpIL2 (Figure 6). Oral administration of SalpIL2, with and 
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a total of 14 days prior to collection of tumor and hepatic lymphocyte data (see diagram above). Tumor number (A) and tumor volume (B) in animals fed a diet consisting of 
Br with and without SalpIL2. hepatic natural killer (nK) (C), cD8+ T (D), and cD4+ T cell response (E) to SalpIL2 with and without Br oil on Day 14.
Notes: Bars represent statistical significance between groups. Data was normalized to percent of control and presented as ± standard error of mean from three independent 
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Figure 5 Effect of black raspberry (BR; Rubus occidentalis) seed oil and SalpIL2 on the prevention of experimental hepatic metastases in mice. A single oral administration of 
SalpIL2 and initiation of Br (shaded area) seed oil diet 10% w/w was given to animals on Day -7. On Day 0, 5x104 MCA-38 cells were injected intrasplenically and animals were 
maintained for 14 additional days. Tumor and hepatic lymphocyte data collected on Day 14 (see diagram above). Tumor number (A) and tumor volume (B) in animals fed a diet 
consisting of Br with and without SalpIL2. hepatic natural killer (nK) (C), cD8+ T (D), and cD4+ T cell response (E) to SalpIL2 and Br oil in tumor burden mice on Day 21. 
Notes: Bars represent statistical significance between groups. Data was normalized to percent of control and presented as ± standard error of mean from three independent 
experiments with n = 5 mice per group.
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Figure 6 Effect of black raspberry (BR; Rubus occidentalis) seed oil on the splenic lymphocyte response to SalpIL2 in mice. Splenic natural killer (nK) (A), cD8+ T (B), and 
cD4+ T cell populations (C) as determined by flow cytometry in response in animals fed a diet consisting of BR seed oil 10% w/w (), administered as single oral dose of 
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without BR oil, induced a significant increase in splenic NK 
cells after as short a time period as 3 days and peaked 7 days 
after oral inoculation (Figures 1A and 6A). Tumor delivery 
at the peak of the NK response to SalpIL2 and BR (Figure 5) 
resulted in greater than 90% reduction of tumor, though there 
was no statistical difference between the two Salmonella 
groups. BR oil alone, however, significantly reduced tumor 
volume suggesting BR oil can induce a preventive effect to 
the liver within 7 days to reduce tumor growth.
Not all oils tested in our models were shown to have 
measureable antitumor effects. MT oil, which had the least 
detectable amount of lipid soluble antioxidants, did not 
provide any protection against hepatic metastasis. Extracts 
from milk thistle seeds have shown antiproliferative effects 
with colon cancer cell lines and showed synergism with the 
chemotherapeutics doxorubicin and paclitaxel in vitro.40 Most 
importantly milk thistle extracts have demonstrated promise 
as adjuvant treatment with minimal adverse effects in human 
clinical trials as reviewed by Tamayo and Diamond.41 Silibinin, 
a flavinoid contained in MT seeds has been shown to inhibit 
tumorigenesis in rats42 and promotes cell cycle arrest of human 
colon cancer cells.43 Our results with MT oil seem to contradict 
previous reports, however, mice were only fed the diet of MT oil 
1 week prior to tumor injection, whereas others dosed silibinin 
for 3 weeks prior to prostate tumor xenograft.44 Even though 
our tumor cells must survive metastasis from the spleen to the 
liver, the exposure to MT oil appeared to have little effect on 
tumor cell death or survival. In contrast, MT oil treatment alone 
slightly increased tumor burden and reversed the antitumor 
efficacy of SalpIL2 in our model. Silibinin has been described 
to be hepatoprotectant against infection and may have blocked 
the ability of SalpIL2 to mount an antitumor response, perhaps 
by enhancing host resistance to infection in the liver.45,46
In these studies, we show antioxidant oils with SalpIL2 
induce a robust NK cell-mediated response and reduction of 
tumor burden. By administering SalpIL2 and the antioxidant oil 
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Figure 7 Milk thistle (MT; Silybum marianum) seed oil inhibits SalpIL2-dependent prevention of experimental hepatic metastases in mice. A single oral administration of SalpIL2 and 
initiation of MT (shaded area) seed oil diet 10% w/w was given to animals on Day -7. On Day 0, 5 × 104 MCA-38 cells were injected intrasplenically and animals were maintained 
for 14 additional days. Tumor and hepatic lymphocyte data collected on Day 21 (see diagram above). Tumor number (A) and tumor volume (B) in animals fed a diet consisting of 
MT oil and or SalpIL2. natural killer (nK) (C), cD8+ T (D), and cD4+ T cell response (E) to SalpIL2 and MT oil on Day 21. 
Notes: Bars represent statistical significance between groups. Data was normalized to percent of control and presented as ± standard deviation from one experiment with 
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diet 3 days after establishment of hepatic metastases, we model 
the clinical situation in which patients are diagnosed with distant 
metastases. In the clinical setting, soon after surgical resection, 
systemic chemotherapy is used to reduce undetectable micro-
metastases or unresectable metastatic lesions. Despite these 
efforts, patients diagnosed with metastatic colorectal cancer 
have an average 3-year survival rate of 11%.47 Because there 
is a propensity for malignant colon cancers to form hepatic 
metastases, the use of S. enterica, whose primary site of infec-
tion is within the liver, is an ideal vector for colorectal hepatic 
metastases. Furthermore, based on the data in this report, the 
administration of antioxidant oils with SalpIL2 induces a more 
robust NK cell response as compared to SalpIL2 alone; even 
when tumors are not present. Hence, when administered prior 
to tumor development or under low metastatic tumor burden, 
SalpIL2 with antioxidant oils may create an environment in the 
liver that is abundant with NK cells and thus inhospitable for 
tumor metastasis. By reducing the occurrence of hepatic metas-
tasis, SalpIL2 and antioxidant oils may provide a significant 
survival benefit, perhaps similar to the 90% 5-year survival of 
colon cancer patients without metastatic disease.47 Therefore, 
additional studies on the mechanism by which antioxidant oils 
and SalpIL2 suppress metastatic tumors is warranted.
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